CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)

#1714

Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.

Aim(s): CALM-NET (NCT02075606) investigates the benefit of enumerating CTCs to predict symptom control in midgut NET pts on LAN.

Materials and methods: This study enrolled 50 pts with somatostatin receptor positive, functioning midgut G1/G2 NET. Pts were not permitted to receive interferon, chemotherapy, chemoembolisation or radionuclide therapy within 3 mo of study entry; prior somatostatin analogue treatment was permitted but after washout. Pts receive LAN at a starting dose of 120mg/28d; after 3 injections, dose can be maintained or down-titrated to 60 or 90mg/28d for remainder of the study. CTC levels are measured at 1, 5, 17, 25 & 53wks, and pts report on symptom control. Frequency/severity of symptoms are taken daily in the first 16wks, on days 11-17 for subsequent injections and days 11-28 after wk49. CT/MRI scans are used to assess progression at wks25 & 53. Impact on quality of life is assessed via the EORTC QLQ-NET21 and QLQ-C30.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meyer T

Authors: Meyer T, Higgs K, Hickling M, Houchard A,

Keywords: midgut neuroendocrine tumor, CTC, lanreotide,